Abstract
We have studied the in vitro effects of carbovir as compared to 3'-azido-3'-deoxythymidine (AZT) on the growth of clonal bone marrow-derived hematopoietic progenitor cells. (-)Carbovir, the enantiomer with anti-human immunodeficiency virus (HIV) activity, exhibited significantly less toxicity to hematopoietic cells than AZT. These in vitro studies suggest that (-)carbovir will exhibit less hematologic toxicity in the therapy of patients infected with HIV either as a single agent or in combination with other agents that inhibit HIV proliferation.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Bone Marrow Cells*
-
Cell Division / drug effects
-
Colony-Forming Units Assay
-
Dideoxynucleosides / administration & dosage
-
Dideoxynucleosides / adverse effects*
-
Dideoxynucleosides / pharmacology
-
Dose-Response Relationship, Drug
-
Erythroid Precursor Cells / cytology
-
Erythroid Precursor Cells / drug effects
-
Granulocytes / cytology
-
Granulocytes / drug effects
-
Hematopoietic Stem Cells / cytology
-
Hematopoietic Stem Cells / drug effects*
-
Humans
-
Macrophages / cytology
-
Macrophages / drug effects
-
Megakaryocytes / cytology
-
Megakaryocytes / drug effects
-
Zidovudine / administration & dosage
-
Zidovudine / adverse effects*
-
Zidovudine / pharmacology
Substances
-
Dideoxynucleosides
-
carbovir
-
Zidovudine